Advancing Alternative Bioequivalence for OINDPs
Nanopharm & Fluidda explore FDA’s progress in alternative bioequivalence for OINDPs, Model Master Files (MMF), and future regulatory pathways.
FDA’s Evolving Stance on In-Silico Studies in Bioequivalence Testing
Discover how the FDA’s evolving view on in-silico methods, with insights from Nanopharm and FLUIDDA, impacts bioequivalence and generic drugs.
Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack
Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.
Nanopharm & FLUIDDA Interviews on SmartTrack: In Vitro-In Silico Approaches for Demonstrating Bioequivalence for OINDP
To support generic drug companies in obtaining a market license for their orally inhaled drug products (OIDPs), Nanopharm and FLUIDDA entered into an exclusive collaboration to combine Nanopharm’s SmartTrack™ with FLUIDDA’s Functional Respiratory Imaging technology to create a unique in-vitro in-silico platform. This allows pharma companies to shorten their clinical pathways – and potentially avoid […]
A Holistic Demonstration of SmartTrack™ and New Ways of Collaborating Combine for a Successful FDA Workshop
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Intranasal Drug Delivery: Unravelling the Nanoparticle Formulation Puzzle
Navigate the complexities of formulating nanoparticles for intranasal drug delivery with expert insights
Novel Aerosol Apparatus for Inhaler Testing in OINDPs
Explore a case study for UniDose in the development of a novel aerosol collection apparatus for dissolution testing of orally inhaled drugs.
Nanopharm Value Creation with OINDP Innovation
Discover Nanopharm’s pre-clinical OINDP solutions using SmartTrack for cutting-edge MDI development, transforming respiratory drug research.
Nanopharm Case Study on Computational Modelling
Accelerate injectable drug reformulation for nasal delivery using modelling. Uncover clinical benefits and innovation in nasal pharmaceuticals.
